J Cancer 2023; 14(4):591-599. doi:10.7150/jca.81054 This issue Cite
1. Department of Otolaryngology-Head Neck Surgery, The Affiliated Chaohu Hospital of Anhui Medical University, Hefei, Anhui, 238001, P.R. China
2. Department of Otorhinolaryngology Head and Neck Surgery, The Second People's Hospital of Hefei, Hefei, Anhui, 230001, P.R. China.
3. Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, P.R. China
4. Anhui Province Key Laboratory of Translational Cancer Research, Bengbu Medical College, Bengbu, Anhui, 233030, P.R. China
5. Laboratory of Molecular Biology and Department of Biochemistry, Anhui Medical University, Hefei, Anhui, 230032, P.R. China
6. Department of Otolaryngology-Head Neck Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, P.R. China
# Contributed equally
An increasing number of studies have shown that USP9X is closely related to cancer. However, its role in carcinogenesis and progression of laryngeal cancer has not yet been investigated. In this study, we found that USP9X was upregulated in laryngeal cancer tissues. The expression of USP9X was significantly correlated with degree of laryngeal cancer differentiation and lymphatic metastasis. USP9X knockdown led to a decrease in the ability of proliferation, migration, and invasion of FaDu cells. The proportion of FaDu apoptotic cells increased by interfering with the endogenous expression of USP9X. We speculated that inhibiting USP9X might induce apoptosis in FaDu cells by downregulating Mcl-1 and upregulating Bax protein expression. Our findings for the first time suggest the expression level and trend of USP9X in laryngeal cancer tissue and USP9X may plays an important role in promoting the occurrence and progression of laryngeal cancer. USP9X may be a potential target for intervention in treatment of laryngeal cancer.
Keywords: laryngeal cancer, USP9X, proliferation, migration, invasion, Mcl-1